Table 2.

Comparisons of stage III NSCLC patients who received surveillance brain MRI and those who did not.

	No Surveillance brain MRI (n = 137)	Surveillance brain MRI (n = 23)
Developed BrMs: number (%)
Yes	31 (22.6%)	6 (26.1%)
No	106 (77.4%)	17 (73.9%)
Incidence of BrMs at 2-years: % (95% CI)	15.0% (9.6-21.7)	28.5% (11.1-48.9)ns
BrMs: number (%)
Symptomatic	14 (45.2%)	3 (50.0%)
Asymptomatic	17 (54.8%)	3 (50.0%)

BrMs, brain metastases; ns, non-significant.